Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| NF-E2-Related Factor 2 | 13 | 2024 | 77 | 4.860 |
Why?
|
| Nitric Oxide Synthase Type I | 14 | 2022 | 56 | 4.380 |
Why?
|
| Gastroparesis | 9 | 2022 | 9 | 4.290 |
Why?
|
| Nitric Oxide | 13 | 2024 | 316 | 3.580 |
Why?
|
| Gastric Emptying | 9 | 2021 | 13 | 2.800 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 2022 | 94 | 2.720 |
Why?
|
| Porphyromonas gingivalis | 4 | 2024 | 32 | 1.940 |
Why?
|
| Acrolein | 3 | 2024 | 16 | 1.810 |
Why?
|
| Saliva | 3 | 2023 | 107 | 1.510 |
Why?
|
| Periodontal Diseases | 4 | 2017 | 49 | 1.310 |
Why?
|
| Diabetes Complications | 3 | 2019 | 90 | 1.250 |
Why?
|
| Pylorus | 3 | 2018 | 5 | 1.180 |
Why?
|
| Pterins | 3 | 2018 | 4 | 1.130 |
Why?
|
| Antioxidants | 6 | 2021 | 416 | 1.050 |
Why?
|
| Stomach | 4 | 2019 | 45 | 1.020 |
Why?
|
| Mesenteric Arteries | 3 | 2015 | 20 | 0.920 |
Why?
|
| Animals | 34 | 2024 | 15081 | 0.910 |
Why?
|
| Estradiol | 7 | 2013 | 262 | 0.910 |
Why?
|
| Gastrointestinal Motility | 3 | 2018 | 18 | 0.900 |
Why?
|
| Intestinal Mucosa | 1 | 2024 | 122 | 0.890 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 269 | 0.820 |
Why?
|
| Mice, Knockout | 9 | 2022 | 933 | 0.800 |
Why?
|
| Obesity | 2 | 2020 | 1067 | 0.780 |
Why?
|
| Maleimides | 1 | 2020 | 13 | 0.750 |
Why?
|
| Apolipoproteins E | 4 | 2015 | 129 | 0.740 |
Why?
|
| Mice | 14 | 2022 | 5913 | 0.740 |
Why?
|
| Mouth | 3 | 2017 | 45 | 0.730 |
Why?
|
| Signal Transduction | 4 | 2024 | 1908 | 0.710 |
Why?
|
| Hyperglycemia | 1 | 2020 | 55 | 0.700 |
Why?
|
| Pyloric Antrum | 3 | 2022 | 6 | 0.700 |
Why?
|
| Calcitonin Gene-Related Peptide | 6 | 2013 | 11 | 0.670 |
Why?
|
| Indoles | 1 | 2020 | 158 | 0.670 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 664 | 0.650 |
Why?
|
| Female | 28 | 2024 | 20969 | 0.650 |
Why?
|
| Bacteroidaceae Infections | 2 | 2015 | 6 | 0.650 |
Why?
|
| Oxidative Stress | 5 | 2024 | 938 | 0.640 |
Why?
|
| Rats | 17 | 2024 | 3483 | 0.640 |
Why?
|
| Diabetes Mellitus | 3 | 2018 | 485 | 0.600 |
Why?
|
| Muscle Relaxation | 5 | 2019 | 19 | 0.600 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2016 | 5 | 0.550 |
Why?
|
| Xerostomia | 1 | 2016 | 3 | 0.550 |
Why?
|
| Nitrergic Neurons | 2 | 2012 | 5 | 0.500 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 61 | 0.490 |
Why?
|
| Gastric Mucosa | 2 | 2012 | 51 | 0.490 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2016 | 1618 | 0.490 |
Why?
|
| Progesterone | 5 | 2013 | 113 | 0.450 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 1609 | 0.400 |
Why?
|
| Estrogens | 2 | 2013 | 202 | 0.390 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 105 | 0.390 |
Why?
|
| Receptors, LDL | 1 | 2011 | 30 | 0.380 |
Why?
|
| Kidney Diseases | 1 | 2013 | 167 | 0.380 |
Why?
|
| Diabetic Neuropathies | 1 | 2010 | 11 | 0.370 |
Why?
|
| Gonadal Steroid Hormones | 4 | 2020 | 51 | 0.370 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.360 |
Why?
|
| Cytokines | 3 | 2024 | 602 | 0.360 |
Why?
|
| Sex Characteristics | 2 | 2011 | 230 | 0.350 |
Why?
|
| Hormones | 1 | 2009 | 55 | 0.330 |
Why?
|
| Endothelium, Vascular | 5 | 2020 | 237 | 0.330 |
Why?
|
| Atherosclerosis | 3 | 2015 | 134 | 0.330 |
Why?
|
| Humans | 15 | 2024 | 37093 | 0.290 |
Why?
|
| Blotting, Western | 5 | 2014 | 859 | 0.280 |
Why?
|
| Risk Factors | 6 | 2023 | 3562 | 0.280 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2006 | 9 | 0.270 |
Why?
|
| Flutamide | 1 | 2005 | 7 | 0.260 |
Why?
|
| Diet, Protein-Restricted | 1 | 2005 | 6 | 0.260 |
Why?
|
| Aorta | 3 | 2015 | 167 | 0.250 |
Why?
|
| Treponema denticola | 2 | 2015 | 5 | 0.250 |
Why?
|
| Sex Factors | 4 | 2013 | 898 | 0.250 |
Why?
|
| Aging | 2 | 2009 | 664 | 0.240 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2015 | 22 | 0.240 |
Why?
|
| Blood Glucose | 3 | 2011 | 353 | 0.240 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2024 | 62 | 0.230 |
Why?
|
| RNA, Messenger | 4 | 2018 | 1207 | 0.230 |
Why?
|
| Gene Expression | 3 | 2021 | 674 | 0.230 |
Why?
|
| Reactive Oxygen Species | 2 | 2024 | 461 | 0.220 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2016 | 67 | 0.220 |
Why?
|
| Pain | 1 | 2006 | 251 | 0.220 |
Why?
|
| Dental Caries | 1 | 2024 | 57 | 0.220 |
Why?
|
| Male | 17 | 2015 | 20025 | 0.220 |
Why?
|
| Lipopolysaccharides | 1 | 2024 | 220 | 0.210 |
Why?
|
| Periodontitis | 2 | 2014 | 53 | 0.210 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 2721 | 0.210 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 284 | 0.210 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2022 | 32 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 643 | 0.200 |
Why?
|
| Superoxide Dismutase | 2 | 2012 | 155 | 0.190 |
Why?
|
| Epithelial Cells | 1 | 2024 | 384 | 0.190 |
Why?
|
| Cell Line | 1 | 2024 | 1354 | 0.180 |
Why?
|
| Curcumin | 1 | 2021 | 74 | 0.180 |
Why?
|
| Down-Regulation | 2 | 2013 | 435 | 0.180 |
Why?
|
| Weight Gain | 1 | 2021 | 136 | 0.180 |
Why?
|
| Vasodilation | 3 | 2010 | 65 | 0.170 |
Why?
|
| Dimerization | 2 | 2010 | 112 | 0.160 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 95 | 0.160 |
Why?
|
| Glucose | 1 | 2020 | 230 | 0.160 |
Why?
|
| Body Weight | 2 | 2011 | 434 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2020 | 184 | 0.160 |
Why?
|
| Vasomotor System | 2 | 2011 | 4 | 0.160 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 47 | 0.160 |
Why?
|
| Prevalence | 1 | 2023 | 1455 | 0.160 |
Why?
|
| Brain | 1 | 2006 | 1346 | 0.160 |
Why?
|
| Rats, Wistar | 1 | 2018 | 233 | 0.160 |
Why?
|
| Disease Models, Animal | 4 | 2012 | 1371 | 0.150 |
Why?
|
| Hypertension | 1 | 2005 | 796 | 0.150 |
Why?
|
| Endothelial Cells | 1 | 2020 | 308 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 169 | 0.150 |
Why?
|
| NG-Nitroarginine Methyl Ester | 4 | 2007 | 36 | 0.150 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 42 | 0.140 |
Why?
|
| Myositis | 2 | 2006 | 7 | 0.140 |
Why?
|
| Hyperalgesia | 2 | 2006 | 18 | 0.140 |
Why?
|
| Chronic Disease | 3 | 2015 | 484 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 448 | 0.130 |
Why?
|
| Fusobacterium nucleatum | 1 | 2015 | 8 | 0.130 |
Why?
|
| Biofilms | 1 | 2017 | 168 | 0.130 |
Why?
|
| Bacteroidetes | 1 | 2015 | 9 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2017 | 661 | 0.130 |
Why?
|
| alpha-Globins | 1 | 2014 | 4 | 0.120 |
Why?
|
| Adrenomedullin | 3 | 2010 | 4 | 0.120 |
Why?
|
| Gene Deletion | 1 | 2015 | 166 | 0.120 |
Why?
|
| Logistic Models | 1 | 2017 | 923 | 0.120 |
Why?
|
| Placenta | 3 | 2004 | 97 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 54 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2014 | 63 | 0.120 |
Why?
|
| Colon | 1 | 2014 | 103 | 0.120 |
Why?
|
| Ovariectomy | 3 | 2010 | 105 | 0.110 |
Why?
|
| Inflammation | 2 | 2015 | 618 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2010 | 187 | 0.110 |
Why?
|
| Myocardial Contraction | 1 | 2013 | 48 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2018 | 426 | 0.110 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 37 | 0.110 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2012 | 9 | 0.110 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 32 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 186 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 36 | 0.100 |
Why?
|
| Random Allocation | 1 | 2012 | 139 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2012 | 550 | 0.100 |
Why?
|
| Peptide Fragments | 3 | 2013 | 308 | 0.100 |
Why?
|
| Receptors, Calcitonin | 2 | 2009 | 3 | 0.100 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2011 | 24 | 0.100 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2011 | 17 | 0.100 |
Why?
|
| Heart | 1 | 2013 | 180 | 0.100 |
Why?
|
| Peptides | 2 | 2005 | 320 | 0.100 |
Why?
|
| Pregnancy | 6 | 2010 | 1549 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2017 | 642 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 421 | 0.090 |
Why?
|
| Coronary Disease | 1 | 2012 | 124 | 0.090 |
Why?
|
| Uterine Artery | 1 | 2010 | 2 | 0.090 |
Why?
|
| Methotrexate | 1 | 2010 | 23 | 0.090 |
Why?
|
| Protein Structure, Quaternary | 1 | 2010 | 64 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 562 | 0.090 |
Why?
|
| Membrane Proteins | 3 | 2010 | 517 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 142 | 0.090 |
Why?
|
| Hypoxanthines | 1 | 2010 | 3 | 0.090 |
Why?
|
| GTP Cyclohydrolase | 1 | 2010 | 4 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 76 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2005 | 646 | 0.090 |
Why?
|
| Trigeminal Ganglion | 2 | 2006 | 13 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 1015 | 0.080 |
Why?
|
| Ganglia, Spinal | 1 | 2009 | 37 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2010 | 208 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2009 | 86 | 0.080 |
Why?
|
| Vasodilator Agents | 2 | 2010 | 56 | 0.080 |
Why?
|
| Middle Aged | 3 | 2017 | 10129 | 0.080 |
Why?
|
| Tetrodotoxin | 1 | 2007 | 22 | 0.070 |
Why?
|
| Gestational Age | 2 | 2005 | 190 | 0.070 |
Why?
|
| Pressure | 1 | 2007 | 43 | 0.070 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 58 | 0.070 |
Why?
|
| Muscle Contraction | 1 | 2007 | 66 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2007 | 184 | 0.070 |
Why?
|
| Adult | 3 | 2017 | 11712 | 0.070 |
Why?
|
| Neuropeptides | 1 | 2005 | 59 | 0.070 |
Why?
|
| Enzyme Inhibitors | 3 | 2003 | 433 | 0.060 |
Why?
|
| Antibodies, Bacterial | 2 | 2015 | 109 | 0.060 |
Why?
|
| Oral Hygiene | 1 | 2024 | 17 | 0.060 |
Why?
|
| Fetus | 1 | 2004 | 105 | 0.060 |
Why?
|
| Beverages | 1 | 2024 | 68 | 0.060 |
Why?
|
| Oral Health | 1 | 2024 | 68 | 0.060 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2002 | 2 | 0.050 |
Why?
|
| Fetal Growth Retardation | 1 | 2003 | 50 | 0.050 |
Why?
|
| Cattle | 1 | 2024 | 477 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2003 | 61 | 0.050 |
Why?
|
| Fertility | 1 | 2002 | 59 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2002 | 343 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2002 | 162 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 623 | 0.040 |
Why?
|
| Nitroglycerin | 1 | 1996 | 7 | 0.030 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1996 | 21 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1996 | 44 | 0.030 |
Why?
|
| Bone Density | 1 | 1996 | 75 | 0.030 |
Why?
|
| Gingival Diseases | 1 | 2015 | 3 | 0.030 |
Why?
|
| Child | 1 | 2024 | 3131 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 24 | 0.030 |
Why?
|
| Alveolar Bone Loss | 1 | 2015 | 18 | 0.030 |
Why?
|
| Serum Amyloid A Protein | 1 | 2015 | 14 | 0.030 |
Why?
|
| Bacteremia | 1 | 2015 | 30 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2015 | 64 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 82 | 0.030 |
Why?
|
| Comet Assay | 1 | 2014 | 76 | 0.030 |
Why?
|
| Bone Resorption | 1 | 2014 | 8 | 0.030 |
Why?
|
| Gingivitis | 1 | 2014 | 7 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 53 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 103 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 1039 | 0.030 |
Why?
|
| Behavior, Animal | 2 | 2006 | 314 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 237 | 0.030 |
Why?
|
| Sarcomeres | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cell Separation | 1 | 2013 | 93 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 2004 | 207 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 601 | 0.030 |
Why?
|
| Litter Size | 2 | 2003 | 15 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2013 | 89 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 96 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2013 | 101 | 0.030 |
Why?
|
| DNA Damage | 1 | 2014 | 352 | 0.030 |
Why?
|
| Prognosis | 1 | 2014 | 739 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 974 | 0.030 |
Why?
|
| Aged | 2 | 2014 | 6741 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 267 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 864 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 166 | 0.020 |
Why?
|
| Glyburide | 1 | 2010 | 8 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2010 | 33 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 480 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 2379 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 2006 | 14 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2006 | 65 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2006 | 80 | 0.020 |
Why?
|
| Masseter Muscle | 1 | 2005 | 4 | 0.020 |
Why?
|
| Afferent Pathways | 1 | 2005 | 37 | 0.020 |
Why?
|
| Neurons, Afferent | 1 | 2005 | 43 | 0.020 |
Why?
|
| Substance P | 1 | 2005 | 26 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 893 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4268 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 5363 | 0.010 |
Why?
|
| Fetal Weight | 1 | 2003 | 9 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 47 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 513 | 0.010 |
Why?
|
| Systole | 1 | 2003 | 61 | 0.010 |
Why?
|
| Trophoblasts | 1 | 2002 | 24 | 0.010 |
Why?
|
| Labor, Obstetric | 1 | 2002 | 16 | 0.010 |
Why?
|
| Mifepristone | 1 | 2002 | 34 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 189 | 0.010 |
Why?
|
| Growth | 1 | 2002 | 12 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 1742 | 0.010 |
Why?
|
| United States | 1 | 2012 | 4223 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 1369 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 130 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 212 | 0.010 |
Why?
|
| Birth Weight | 1 | 2002 | 90 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 290 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 1996 | 75 | 0.010 |
Why?
|
| Arginine | 1 | 1996 | 73 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1996 | 177 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 227 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 1996 | 128 | 0.010 |
Why?
|